Pluri completes first phase of program with Resbiomed Technologies OOD

Pluri (PLUR) announced the completion of the first phase of its program with Resbiomed Technologies OOD, a European biotechnology company developing extracellular-matrix-based biomaterials and biologics for regenerative medicine. The program is being executed through Pluri’s contract development and manufacturing division, PluriCDMO. Under the program, Pluri is applying its proprietary placenta-based technologies and advanced bioprocessing expertise to support Resbiomed in establishing protocols for tissue extraction, separation and processing designed to preserve, concentrate and enhance endogenous collagen components and yield high-quality biological materials for diverse regenerative-medicine applications.